Clinical Trial Update: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome [Phase 2]

View source ↗

Summary

This clinical trial update describes KYSA-8, an anti-CD19 CAR T-cell therapy from Kyverna Therapeutics, being studied for treatment-refractory Stiff-Person Synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stiff-person Syndrome

Drugs mentioned

• KYSA-8

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Stiff-Person Syndrome, SPS | Phase 2 | Status: ACTIVE_NOT_RECRUITING